Hours before a pivotal court hearing, Novo Nordisk has increased its offer for obesity biotech Metsera to as much as $10 billion, trying to outdo

In Laura Jensen’s first 90 days at GoodRx, she’s found herself spending quite a lot of time on what’s happening in Washington, DC. Jensen joined

The ESSENCE trial of Sarepta’s Vyondys 53 and Amondys 45 failed to hit its objective, placing their FDA accelerated approvals at risk.

Figuring out how to transport genetic medicines to the right parts of the body remains one of the great technical challenges constraining CRISPR’s potential. Now,

CDMO executives say they are unfazed about the wave of pharma companies boosting their internal manufacturing capacity as they onshore to the US, noting this